Mylan Laboratories Limited v. Food and Drug Administration, 910 F. Supp. 2d 299

This dispute concerns 180-day exclusivity for valsartan; FDA ruled Ranbaxy did not forfeit exclusivity due to USP monograph changes delaying tentative approval.
Mylan sued under the Administrative Procedure Act and Hatch-Waxman Act seeking to set aside FDA's decision and obtain final approval for its ANDA.
Ranbaxy was the first applicant with a paragraph IV certification and thus eligible for 180-day exclusivity, but did not obtain tentative approval by the 30-month date.
May 1, 2007, the USP monograph for valsartan became official, prompting Ranbaxy to amend its ANDA; FDA subsequently reviewed data and delayed tentative approval.
FDA tentatively approved Ranbaxy's ANDA in October 2007; ranbaxy’s delay and data review contributed to the forfeiture analysis; Mylan sought expedited relief in 2012.
On September 28, 2012, FDA concluded Ranbaxy did not forfeit exclusivity, tentatively approved Mylan's ANDA, and provided confidential basis for its decision.

Issue	Plaintiff's Argument	Defendant's Argument	Held
Was FDA's causation finding reasoned?	Mylan argues no rational basis for tying monograph to delay.	FDA contends seven-factor test supports causation and delay due to compliance efforts.	Yes; FDA's causation reasoning is rational and supported by the record.
Did FDA adequately apply the seven-factor test?	Mylan contends factor 5 (consistency with pre-existing requirements) was missing.	FDA relied on six factors and explained rationale other than a formulaic count.	FDA's decision reasonably applied most factors; the court finds the analysis adequate.
Does the decision align with Hatch-Waxman congressional intent?	Mylan asserts the decision undermines incentives for generic competition.	Justified by exception for delays caused by changes in approval requirements.	No reversal; decision consistent with Congress's exception for regulatory changes.
Was Mylan's new 'active pursuit' argument waived?	Ranbaxy not actively pursuing approval should yield immediate final approval for Mylan.	Waived due to failure to raise earlier; remedy not properly preserved.	Waived; court declines to consider this new argument.
Does Mylan suffer irreparable harm to justify injunctive relief?	Loss of potential sales and statutory entitlement constitute irreparable harm.	Harm is economic and insufficient to prove irreparable harm.	Irreparable harm not shown; injunction denied.

Winter v. NRDC, 555 U.S. 7 (U.S. 2008) (four-factor test for preliminary injunctions; deference to agency where appropriate)
Fox v. Clinton, 684 F.3d 67 (D.C. Cir. 2012) (deference to agency expertise; need for a rational decision path)
Dickson v. Sec'y of Def., 68 F.3d 1396 (D.C. Cir. 1995) (requirement of a rational connection between facts and decision)
Transcon. Gas Pipe Line Corp. v. FERC, 518 F.3d 916 (D.C. Cir. 2008) (demonstrates ability to discern an agency's path)
Chevron U.S.A., Inc. v. Nat. Res. Def. Council, Inc., 467 U.S. 837 (U.S. 1984) (delegation of interpretive authority to agency when reasonable)
Hi-Tech Pharmacal Co. v. FDA (Hi-Tech II), 587 F. Supp. 2d 13 (D.D.C. 2008) (APA review framework for agency actions)